The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]


Variant: NM_000162.5(GCK):c.1133C>T (p.Ala378Val)

CA341585

21076 (ClinVar)

Gene: GCK
Condition: monogenic diabetes
Inheritance Mode: Semidominant inheritance
UUID: ee600241-27a2-46f8-8e47-92684c9a911a

HGVS expressions

NM_000162.5:c.1133C>T
NM_000162.5(GCK):c.1133C>T (p.Ala378Val)
NC_000007.14:g.44145617G>A
CM000669.2:g.44145617G>A
NC_000007.13:g.44185216G>A
CM000669.1:g.44185216G>A
NC_000007.12:g.44151741G>A
NG_008847.1:g.48807C>T
NG_008847.2:g.57554C>T
ENST00000395796.8:c.*1131C>T
ENST00000616242.5:c.*253C>T
ENST00000683378.1:n.359C>T
ENST00000336642.9:c.167C>T
ENST00000345378.7:c.1136C>T
ENST00000403799.8:c.1133C>T
ENST00000671824.1:c.1196C>T
ENST00000672743.1:n.145C>T
ENST00000673284.1:c.1133C>T
ENST00000336642.8:c.185C>T
ENST00000345378.6:c.1136C>T
ENST00000395796.7:c.1130C>T
ENST00000403799.7:c.1133C>T
ENST00000437084.1:c.1082C>T
ENST00000459642.1:n.513C>T
ENST00000616242.4:c.1130C>T
NM_000162.3:c.1133C>T
NM_033507.1:c.1136C>T
NM_033508.1:c.1130C>T
NM_000162.4:c.1133C>T
NM_001354800.1:c.1133C>T
NM_001354801.1:c.122C>T
NM_001354802.1:c.-8C>T
NM_001354803.1:c.167C>T
NM_033507.2:c.1136C>T
NM_033508.2:c.1130C>T
NM_033507.3:c.1136C>T
NM_033508.3:c.1130C>T
NM_001354803.2:c.167C>T

Pathogenic

Met criteria codes 8
PM2_Supporting PS4 PM3_Supporting PP1_Strong PP4 PP3 PP2 PM5
Not Met criteria codes 1
PM1

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Monogenic Diabetes Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for GCK Version 1.2.0

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Monogenic Diabetes VCEP
The variant in the glucokinase gene, GCK, causes an amino acid change of alanine to valine at codon 378 (p.(Ala378Val)) of NM_000162.5. GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is also predicted to be deleterious by computational evidence, with a REVEL score of 0.967, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant is absent in gnomAD v2.1.1 (PM2_Supporting), and was identified in 9 unrelated individuals with non-autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; PMIDs: 14578306, 25935773, internal lab contributors). One of these individuals has a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6%) (internal lab contributors). It has also been detected in an individual with neonatal diabetes who was homozygous for this variant and had antibody-negative diabetes (PM3_Supporting, PMID: 14578306). This variant also segregated with diabetes, with at least 4 informative meioses in 4 families with MODY (PP1_Strong; internal lab contributors). Additionally, another missense variant, c.1132G>A (p.Ala378Thr) has been interpreted as pathogenic by the ClinGen MDEP and p.Ala378Val has a greater Grantham distance (PM5). In summary, c.1133C>T meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.2.0, approved 6/7/2023): PP1_Strong, PP4, PS4, PM5, PP2, PP3, PM2_Supporting, PM3_Supporting.
Met criteria codes
PM2_Supporting
This variant is absent from gnomAD v2.1.1 (PM2_Supporting).
PS4
This variant was identified in 9 unrelated individuals with non-autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4; PMIDs: 14578306, 25935773, internal lab contributors).
PM3_Supporting
This variant has been detected in an individual with neonatal diabetes who was homozygous for this variant and had negative antibodies (PM3_Supporting, PMID: 14578306)
PP1_Strong
This variant segregated with diabetes, with at least 4 informative meioses in 4 families with MODY (PP1_Strong; internal lab contributors).
PP4
This variant was identified in an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6%) (internal lab contributors).
PP3
This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.967, which is greater than the MDEP VCEP threshold of 0.70 (PP3).
PP2
GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2)
PM5
Another missense variant, c.1132G>A (p.Ala378Thr) has been interpreted as pathogenic by the ClinGen MDEP and p.Ala378Val has a greater Grantham distance. (PM5).
Not Met criteria codes
PM1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
Approved on: 2023-08-08
Published on: 2023-08-08
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.